Merck Says Zetia Buyers Can't Expand Pay-For-Delay Suit

Law360 (July 12, 2019, 4:03 PM EDT) -- Merck & Co. Inc. has asked a Virginia federal judge not to expand multidistrict litigation alleging it conspired with Glenmark Pharmaceuticals Inc. to keep cholesterol drug Zetia off the market using a pay-for-delay agreement, saying buyers can't rope in a distributor and seek new wide-ranging damages.

Zetia purchasers improperly added Glenmark's distributor Par Pharmaceutical Inc. as an alleged co-conspirator in its amended complaint in a last-ditch effort to expand the range of class entities, Merck said in a motion to dismiss the updated case Thursday. The drug wholesalers also can't pursue damages against any seller, regardless of whether it was allegedly...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS